B. Rebrov, S. Kasynets, O. Komarova

Lugansk State Medical University

Introduction. Patients with rheumatoid arthritis (RA) suffer from psychosocial maladaptation due to pain syndrome, limitation of activity with loss of ability to work and social connections. The presence of anxiety-depressive disorders (ADD) increases the incapacity of patients with RA in the first five years of illness from 25.0 to 50.0%

Aim. Optimize RA treatment at an early stage (eRA) in combination with ADD, using a ramipril inhibitor of the angiotensin converting enzyme (ACE) in the treatment complex.

Materials and methods. The examination of 179 patients with undifferentiated arthritis that was treated at the rheumatologic department of the Luhansk Regional Clinical Hospital revealed 95 people with eRA. The age of patients ranged from 22 to 59 years (on average, 41.27 ± 10.41 years), among them 16.8% of men and 83.2% of women aged 40.3 ± 9.22 years and 41.2 ± 10, 27 years old respectively. The duration of the disease – 1-28 months. RA diagnosis was verified according to the criteria of ASR/EULAR, 2010.

The psychological status of all the patients was assessed using questionnaires of proven validity: the scale of hospital anxiety and depression (Hospital Anxiety and Depression Scale, HADS); the presence and severity of depression were assessed on Beck’s scale.

Results. It has been established that patients with eRA with ADD due to complex treatment using ramipril are likely to decrease the morning stiffness, the number of painful and edematous joints, the health status according to VAS and HAQ (p<0.001), the CRP level by 8 times, whereas after the treatment with a standard complex – only by 4 times (p<0.001). It is seen that ESR is almost three times as high as 1.75 (p<0.001) than after the standard complex, DAS28 decreases by 25.0%, TNF-α decreases by 25.0% after a comprehensive treatment with ramipril and 12.0% after the treatment without it.

Also, the use of integrated treatment with ramipril improves the ultrasound scores of patients with eRA and ADD, namely, the decrease of the effusion into the cavity of the joints by 30.0% more than without it (p = 0.002), as well as the number of tenosinovites by 50.0% (p = 0.02), vascularization of the synovial membranes of 2nd and 3rd gradations (p = 0.002), increase in the number of patients without signs of synovial membrane vascularization (p = 0.04). Only in 6.7% of patients who received the standard treatment complex there were found new erosions, indicating the prevention of the appearing of the new erosions and the growth of joint destruction in patients with ramipril intake.

The inclusion of ramipril in the treatment regimen for patients with eRA in combination with ADD contributes to a decrease in the number of points on the Beck’s questionnaire from 22.37 ± 7.10 to 10.80 ± 2.90 (p<0.001), whereas without it – only from 22.36 ± 6.20 to 15.86 ± 3.20 points (p = 0.002). In 50.0 % of the patients, as a result of complex treatment with ramipril, the psycho-emotional state (total score on the Beck’s questionnaire <10) was normalized compared with those who received treatment without it (p = 0.04).

Copnclusions. Adding ramipril to the standard threatment course helps to improve the ultrasound picture, to decrease the articular syndrome and leads to the positive dynamics of the inflammatory markers. In patients with early RA the ultrasound of joints can determine the level of disease activity and is a promising noninvasive method of the pharmacotherapy monitoring.

References

1. Bortkevych OP, Shuba NM, Mazurenko OV. Optimization of Monitoring the Course of Rheumatoid Arthritis on the Basis of Ultrasound and Magnetic Resonance Imaging. Ukrainian Medical Journal. 2003;5:61-64. (Russian)
2. Nazarenko GI, Geroeva IB, Khitrova AN, Saykovskaya TV, Glushkov VP. The Value of Ultrasound Diagnosis in Assessment of Rheumatoid Arthritis Activity and Therapeutic Response. Ultrasound and Functional Diagnostics. 2007;5:83-91. (Russian)
3. Karateyev DE. Angiogenesis in Rheumatoid Arthritis. Bulletin of the Russian Academy of Medical Sciences. 2003;7:47-51. (Russian)
4. Karateyev DE, Luchihina EL. The Current State of the Problem of Early Arthritis. Scientific and Practical Rheumatology. 2010;4(2):27-31. (Russian)
5. Kovalenko VM. Rheumatic Diseases of the Joints: Medical and Social Problems in Ukraine and Ways of Their Solution. Ukrainian Rheumatological Journal. 2003;3:3-7. (Ukrainian)
6. Kovalenko VM, Bortkevych OP, Bilyavskaya YV. Modern Aspects of the Diagnosis of Rheumatoid Arthritis. Health of Ukraine. 2010;1:74-77. (Ukrainian)
7. Kovalenko VM, Bortkevych OP, Terzov KA. Defeat of Small Joints in Patients with Rheumatoid Arthritis at an Early Stage of the Disease According to Ultrasound Examination. Problems of Osteology. 2006;9:55-56. (Ukrainian)
8. Lysenko HI, Tkachenko VI. Psychoemotional Aspects of Chronic Pain in Patients with Rheumatoid Arthritis. Health of Ukraine. 2008;5:66-67. (Russian)
9. Nasonov EL. Rheumatoid Arthritis as a General Medical Problem. Therapeutic Archive. 2004;5:5-7. (Russian)
10. Soloviev AH, Reznikov LL, Nazarov PH, Dinarello CA. Proinflammatory Cytokine-inducing Properties of Angiotensin II and the Mechanism of Anticytokine Effects of the Inhibitor of the Angiotensin-converting Enzyme Captopril. Cytokines and Inflammation. 2006;5(3):40-45. (Russian)
11. Zeltyn’ AE, Vel’tishchev DY, Fofanova YS et al. Rheumatoid Arthritis and Depression: Pathogenetic Role of Stress Factors (literature review). Mental Disorders in General Medicine. 2010;1:13-22. (Russian)
12. Shuba NM. Early Rheumatoid Arthritis: Clinical and Pathophysiological Aspects. Art of Treatment. 2004;3:12-15. (Ukrainian)
13. Yaremenko OB. Early Rheumatoid Arthritis: Diagnosis and Treatment. Art of Treatment. 2004;3:38-45. (Russian)
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. https://doi.org/10.1002/art.27584
15. van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recentonset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56(2):433-440. https://doi.org/10.1002/art.22380
16. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokinesin the kidney. Kidney Int Suppl. 2002;82:12-22. https://doi.org/10.1046/j.1523-1755.62.s82.4.x
17. Lin EH, Tang L, Katon W, Hegel MT, Sullivan MD, Unützer J. Arthritis pain and disability: response to collaborative depression care. Gen Hosp Psychiatry. 2006;28(6):482-486. https://doi.org/10.1016/j.genhosppsych.2006.08.006
18. Jezova D, Ochedalski T, Kiss A, Aguilera G. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol. 1998;10(1):67-72. https://doi.org/10.1046/j.1365-2826.1998.00182.x
19. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population–based study. Arthritis Rheum. 2005;52(3):722-732. https://doi.org/10.1002/art.20878
20. Ichiki T. Role of renin angiotensin system in angiogenesis: it is still elusive. Arterioscler Thromb Vasc Biol. 2004;24(4):622-6224. https://doi.org/10.1161/01.ATV.0000125707.94116.a4
21. Preston Mason R. Optimal Therapeutic Strategy for the Treatment of Patients with Arterial Hypertension and Atherosclerosis: the Focus on the Olmesartan Medoxomil. Therapia. Ukrainian Medical Bulletin. 2011; 7-8: 25-35.
22. Scott DL, Smith C, Kingsley G. What are the consequences of early rheumatoid arthritis for the individual? Best Pract Res Clin Rheumatol. 2005;19(1):117-136. https://doi.org/10.1016/j.berh.2004.08.007